AVXL — Anavex Life Sciences Corp
NASDAQ · Healthcare · Biotechnology
$2.83
-$0.04 (-1.57%)
Anavex Life Sciences Corp (AVXL) is a biotechnology company listed on NASDAQ. It is led by Terrie Kellmeyer Ph.D., based in 630 5th Avenue, New York, NY, United States, 10111, with about 34 employees. Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Net income was -$46.4M. AVXL currently screens at market cap $247.4M.
Use this AVXL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AVXL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AVXL SEC filings page. Lician reads the product cache first so this HTML stays unique to Anavex Life Sciences Corp even when a live quote feed is slow.
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
AVXL Key Statistics
Market Cap
$247.43M
Volume
2.47M
Previous Close
$3.11
Day Range
$3.37 – $3.68
P/B Ratio
1.84
EPS
-$0.54
Revenue
$0.00
Net Income
-$46.38M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
34
AVXL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$46.38M | -$43.00M | -$47.51M | -$47.98M |
| EPS (Diluted) | -$0.54 | -$0.52 | -$0.60 | -$0.62 |
Total Assets
$103.81M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$102.58M
Operating Cash Flow
-$39.04M
Free Cash Flow
$0.00
Anavex Life Sciences Corp Company Information
- Interim Chief Executive Officer
- Terrie Kellmeyer Ph.D.
- Headquarters
- 630 5th Avenue, New York, NY, United States, 10111
- Website
- www.anavex.com
- Phone
- 844 689 3939
- IPO / Founded
- 2006-08-02
- Sector
- Healthcare
- Industry
- Biotechnology